JP2018500343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500343A5 JP2018500343A5 JP2017533772A JP2017533772A JP2018500343A5 JP 2018500343 A5 JP2018500343 A5 JP 2018500343A5 JP 2017533772 A JP2017533772 A JP 2017533772A JP 2017533772 A JP2017533772 A JP 2017533772A JP 2018500343 A5 JP2018500343 A5 JP 2018500343A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- independently selected
- hydroxyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- -1 NR hh Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096374P | 2014-12-23 | 2014-12-23 | |
| US62/096,374 | 2014-12-23 | ||
| US201562102244P | 2015-01-12 | 2015-01-12 | |
| US62/102,244 | 2015-01-12 | ||
| US201562196839P | 2015-07-24 | 2015-07-24 | |
| US62/196,839 | 2015-07-24 | ||
| US201562199661P | 2015-07-31 | 2015-07-31 | |
| US62/199,661 | 2015-07-31 | ||
| PCT/US2015/000212 WO2016105485A2 (en) | 2014-12-23 | 2015-12-23 | Compounds, compositions, and methods for increasing cftr activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500343A JP2018500343A (ja) | 2018-01-11 |
| JP2018500343A5 true JP2018500343A5 (enExample) | 2019-01-31 |
| JP6700284B2 JP6700284B2 (ja) | 2020-05-27 |
Family
ID=55168337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533772A Active JP6700284B2 (ja) | 2014-12-23 | 2015-12-23 | Ｃｆｔｒ活性を増加するための化合物、組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10392372B2 (enExample) |
| EP (1) | EP3237411B1 (enExample) |
| JP (1) | JP6700284B2 (enExample) |
| KR (1) | KR102677444B1 (enExample) |
| CN (1) | CN107207487B (enExample) |
| AU (3) | AU2015371294B2 (enExample) |
| BR (1) | BR112017013710B1 (enExample) |
| ES (1) | ES2962673T3 (enExample) |
| IL (2) | IL252987B (enExample) |
| MA (1) | MA41253A (enExample) |
| MX (1) | MX388421B (enExample) |
| NZ (1) | NZ732701A (enExample) |
| RU (1) | RU2767460C2 (enExample) |
| SA (1) | SA517381828B1 (enExample) |
| SG (1) | SG11201704859UA (enExample) |
| WO (1) | WO2016105485A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| ES2608474T3 (es) | 2010-04-22 | 2017-04-11 | Vertex Pharmaceuticals Incorporated | Proceso de producción de compuestos indol cycloalkylcarboxamido |
| WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| ES2885181T3 (es) | 2014-04-15 | 2021-12-13 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
| CA2952862A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| WO2016054560A1 (en) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CA3000483C (en) | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| MA44126A (fr) * | 2015-12-22 | 2018-10-31 | Proteostasis Therapeutics Inc | Méthodes de traitement de maladies et troubles pulmonaires |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
| MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| SI3519401T1 (sl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
| KR101912153B1 (ko) * | 2016-11-24 | 2018-10-26 | 이진호 | 극지항해용 자기 부상선 |
| CN110267948B (zh) | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3068609A1 (en) * | 2017-07-01 | 2019-01-10 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| CN108440455B (zh) * | 2018-04-11 | 2019-06-14 | 上海馨远医药科技有限公司 | 一种3-氧杂环丁烷羧酸的制备方法 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| ES3014615T3 (en) * | 2018-05-31 | 2025-04-23 | Celltaxis Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| GB201810071D0 (en) | 2018-06-19 | 2018-08-08 | Univ Oslo Hf | Compounds |
| WO2020006269A1 (en) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| EP4100023A4 (en) * | 2020-02-07 | 2024-03-13 | University of South Florida | Inhibition of beta-arrestin oligomerization in tauopathy |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4294798A1 (en) * | 2021-02-19 | 2023-12-27 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
| JP2025505577A (ja) | 2022-02-03 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | （６ａ，１２ａ）－１７－アミノ－１２－メチル－６，１５－ビス（トリフルオロメチル）－１３，１９－ジオキサ－３，４，１８－トリアザトリシクロ［１２．３．１．１２，５］ノナデカ－１（１８），２，４，１４，１６－ペンタエン－６－オールの調製方法及び結晶形態 |
| IL314449A (en) | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4525858A1 (en) | 2022-05-16 | 2025-03-26 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TW202425990A (zh) * | 2022-11-02 | 2024-07-01 | 南韓商日東製藥股份有限公司 | 包含ｃｆｔｒ調節劑化合物之點眼用組成物 |
| CN120136817A (zh) * | 2025-05-16 | 2025-06-13 | 安徽泽升科技股份有限公司 | 一种氧杂环丁烷-3-甲醇和氧杂环丁烷-3-甲醛的制备方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3812225A1 (de) * | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
| BR9606546A (pt) | 1995-08-02 | 1998-07-14 | Uriach & Cia Sa J | Novas carboxamidas com atividade fungicida |
| EP0761654B1 (en) | 1995-08-24 | 2003-06-18 | Basf Aktiengesellschaft | Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides |
| DE69903992T2 (de) * | 1998-04-15 | 2003-08-21 | Pfizer Products Inc., Groton | Heterocyclische Carboxamide |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| EP1394159A1 (fr) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| MXPA06004005A (es) | 2003-10-08 | 2006-06-28 | Vertex Pharma | Moduladores de transportadores con casete de union con atp. |
| JP4869072B2 (ja) | 2003-11-14 | 2012-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| EP1742627A4 (en) | 2004-05-06 | 2009-08-26 | Plexxikon Inc | PDE4B HEMMER AND ITS USE |
| SE0401969D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| JP2006176443A (ja) * | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| JP4822406B2 (ja) | 2005-09-26 | 2011-11-24 | ルネサスエレクトロニクス株式会社 | 表示制御駆動装置および表示システム |
| WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| KR101394245B1 (ko) | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤 |
| TW200815351A (en) * | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| WO2008051757A1 (en) | 2006-10-20 | 2008-05-02 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
| WO2008070739A1 (en) | 2006-12-06 | 2008-06-12 | Cytokinetics, Inc. | Ksp activators |
| CN101778845B (zh) | 2007-06-29 | 2014-06-25 | 爱思开生物制药株式会社 | 用于预防和治疗再狭窄的包含异噁唑衍生物的药物组合物 |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| JP2011511756A (ja) | 2007-08-02 | 2011-04-14 | ナームローゼ・フエンノートチヤツプ・オルガノン | Ｔｒｐｖ１モジュレータとしての５−フェニル−イソオキサゾール−３−カルボキサミド誘導体 |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US20090318429A1 (en) | 2008-04-28 | 2009-12-24 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives |
| AU2010211114A1 (en) | 2009-02-04 | 2011-06-30 | Msd Oss B.V. | Isoxazole-5-carboxamide derivatives |
| MX2011009414A (es) | 2009-03-11 | 2011-10-19 | Kyorin Seiyaku Kk | 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3. |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| IN2012DN00352A (enExample) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| US8569899B2 (en) | 2009-12-30 | 2013-10-29 | Stmicroelectronics, Inc. | Device and method for alignment of vertically stacked wafers and die |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| JP5996532B2 (ja) | 2010-07-15 | 2016-09-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 有害生物防除剤としての新規複素環式化合物 |
| SG193002A1 (en) | 2011-03-10 | 2013-09-30 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
| CA2736441A1 (en) | 2011-04-06 | 2012-10-06 | The Regents Of The University Of California | Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
| JP6138834B2 (ja) | 2012-02-16 | 2017-05-31 | ダウ アグロサイエンシィズ エルエルシー | スルフィルイミン化合物の製造方法 |
| UA110436C2 (en) | 2012-03-06 | 2015-12-25 | Zoetis Llc | Antibacterial phenol compounds |
| WO2013146970A1 (ja) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| WO2014045283A1 (en) | 2012-09-24 | 2014-03-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Restoration of the cftr function by splicing modulation |
| EP2922853A4 (en) | 2012-11-20 | 2016-11-23 | Discoverybiomed Inc | SMALL MOLECULE BICYCLIC AND TRICYCLIC CFTR CORRECTING DEVICES |
| AU2013348018A1 (en) | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| EP2968285A4 (en) | 2013-03-13 | 2016-12-21 | Flatley Discovery Lab | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| EP2968323A4 (en) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| EP2968987A4 (en) | 2013-03-15 | 2017-04-26 | Vertex Pharmaceuticals Inc. | Correctors acting through msd1 of cftr protein |
| US9815825B2 (en) | 2013-03-15 | 2017-11-14 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| EP2994463B1 (en) | 2013-05-07 | 2017-10-25 | Galapagos NV | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| WO2014210159A1 (en) | 2013-06-26 | 2014-12-31 | Proteostasis Therapeutics, Inc. | Methods of modulating cftr activity |
| US9920073B2 (en) | 2013-10-04 | 2018-03-20 | Drexel University | Compositions useful for inhibiting HIV-1 infection and methods using same |
| CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA2952862A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| WO2016054560A1 (en) | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Isoxazole compounds and methods for the treatment of cystic fibrosis |
| CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| WO2016105468A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| WO2017040606A1 (en) | 2015-08-31 | 2017-03-09 | Proteostasis Therapeutics, Inc. | Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders |
| CA3000483C (en) | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| MA44126A (fr) | 2015-12-22 | 2018-10-31 | Proteostasis Therapeutics Inc | Méthodes de traitement de maladies et troubles pulmonaires |
| MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
-
2015
- 2015-12-22 MA MA041253A patent/MA41253A/fr unknown
- 2015-12-23 NZ NZ732701A patent/NZ732701A/en unknown
- 2015-12-23 WO PCT/US2015/000212 patent/WO2016105485A2/en not_active Ceased
- 2015-12-23 BR BR112017013710-0A patent/BR112017013710B1/pt active IP Right Grant
- 2015-12-23 KR KR1020177020139A patent/KR102677444B1/ko active Active
- 2015-12-23 AU AU2015371294A patent/AU2015371294B2/en active Active
- 2015-12-23 MX MX2017008380A patent/MX388421B/es unknown
- 2015-12-23 JP JP2017533772A patent/JP6700284B2/ja active Active
- 2015-12-23 RU RU2017126232A patent/RU2767460C2/ru active
- 2015-12-23 CN CN201580074407.1A patent/CN107207487B/zh active Active
- 2015-12-23 US US15/539,392 patent/US10392372B2/en active Active
- 2015-12-23 EP EP15825647.9A patent/EP3237411B1/en active Active
- 2015-12-23 ES ES15825647T patent/ES2962673T3/es active Active
- 2015-12-23 SG SG11201704859UA patent/SG11201704859UA/en unknown
-
2017
- 2017-06-18 IL IL252987A patent/IL252987B/en active IP Right Grant
- 2017-06-26 SA SA517381828A patent/SA517381828B1/ar unknown
-
2019
- 2019-07-12 US US16/510,406 patent/US11098035B2/en active Active
-
2020
- 2020-08-02 IL IL276426A patent/IL276426A/en unknown
- 2020-10-12 AU AU2020256305A patent/AU2020256305A1/en not_active Abandoned
-
2022
- 2022-09-06 AU AU2022228100A patent/AU2022228100A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500343A5 (enExample) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2016006118A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2016515560A5 (enExample) | ||
| JP2014015465A5 (enExample) | ||
| JP2015537008A5 (enExample) | ||
| JP2013501100A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| HRP20201701T1 (hr) | Aril eteri i njihove uporabe | |
| JP2015504081A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2014521744A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| JP2016503797A5 (enExample) | ||
| JP2016503052A5 (enExample) | ||
| EA201390880A1 (ru) | Имидазопиридины в качестве противовирусных средств против респираторно-синцитиального вируса | |
| JP2015516427A5 (enExample) | ||
| JP2016531868A5 (enExample) | ||
| MY178371A (en) | Pharmaceutical preparation | |
| JP2016523955A5 (enExample) | ||
| JP2017531677A5 (enExample) | ||
| WO2015021396A3 (en) | Tricyclic benzoxaborole compounds and uses thereof |